Webcast ImageWebcast
Jaguar Health: Jaguar Animal Health & Napo Pharmaceuticals Merger Update (Replay)
Jul 28, 2017 at 8:30 a.m. ET
Jaguar Health: Jaguar Animal Health & Napo Pharmaceuticals Merger Update
Friday, July 28, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s non-prescription product for total gut health in equine athletes. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals.

Stock Quote
JAGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Change (%) Stock is Up 0.02 (5.13%)
Data as of 09/22/17 4:00 p.m. ET
Refresh quote
Recent NewsMore News >>
Sep 20, 2017FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication
Read More
Sep 18, 2017Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors
Read More
Sep 18, 2017Jaguar Health Announces Proposed Public Offering of Common Stock
Read More
Sep 15, 2017Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets
Read More
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Jaguar Health, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | E-mail Alerts Email Alerts | Financial Tear Sheet Financial Tear Sheet